Icon (NASDAQ:ICLR) Releases Earnings Results

Posted by Brenda Bartman on May 29th, 2026

Icon (NASDAQ:ICLR – Get Free Report) announced its quarterly earnings results on Wednesday. The medical research company reported $2.52 earnings per share for the quarter, missing the consensus estimate of $2.95 by ($0.43), FiscalAI reports. Icon had a net margin of 7.40% and a return on equity of 10.58%. The business had revenue of $2.11 billion during the quarter, compared to analysts’ expectations of $1.98 billion. During the same quarter in the prior year, the firm earned $3.43 EPS. Icon’s revenue for the quarter was up 2.5% on a year-over-year basis. Icon updated its FY 2026 guidance to 10.000-11.000 EPS.

Icon Trading Up 15.5%

ICLR stock opened at $136.80 on Friday. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon has a 12-month low of $66.57 and a 12-month high of $211.00. The stock has a market cap of $11.05 billion, a price-to-earnings ratio of 22.21, a PEG ratio of 3.09 and a beta of 1.23. The business’s 50-day moving average is $112.28 and its 200 day moving average is $141.50.

Icon News Roundup

Here are the key news stories impacting Icon this week:

Positive Sentiment: ICON reported quarterly revenue of $2.11 billion, above analyst estimates, showing continued demand for its clinical research services despite a softer earnings line. ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation
Positive Sentiment: The company also said it has completed an audit committee investigation, which may help reduce uncertainty around recent reporting concerns. ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation
Neutral Sentiment: ICON’s Q4 earnings call transcript and earnings snapshot are drawing investor attention as traders review management commentary for signs of stabilization after a choppy quarter. ICON Public Limited Company (ICLR) Q4 2025 Earnings Call Transcript
Neutral Sentiment: The company’s short interest update showed no meaningful change in reported short interest, offering little new signal for near-term trading.
Negative Sentiment: Shares came under pressure after ICON missed Q4 earnings expectations, with EPS of $2.52 coming in below the $3.14 consensus. ICON drops after Q4 earnings miss
Negative Sentiment: Management’s FY 2026 EPS guidance of 10.00 to 11.00 also fell short of the Street’s expectation, raising concerns about earnings power even as revenue guidance was roughly in line. ICON drops after Q4 earnings miss
Negative Sentiment: ICON also disclosed a Nasdaq deficiency notice tied to a delayed 2025 annual report filing, adding an overhang for investors. ICON Faces Nasdaq Deficiency Notice as It Delays 2025 Annual Report Filing

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ICLR shares. Royal Bank Of Canada restated a “sector perform” rating on shares of Icon in a research note on Friday. Robert W. Baird set a $119.00 price target on Icon in a research note on Friday, February 13th. Barclays cut their price target on Icon from $200.00 to $120.00 and set an “equal weight” rating for the company in a research note on Monday, March 9th. JPMorgan Chase & Co. lowered their price objective on Icon from $175.00 to $120.00 and set a “neutral” rating on the stock in a report on Monday, May 18th. Finally, Jefferies Financial Group set a $135.00 price objective on Icon and gave the stock a “buy” rating in a report on Monday, February 23rd. Seven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $149.00.

View Our Latest Stock Report on Icon

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ICLR. WINTON GROUP Ltd acquired a new position in shares of Icon during the 2nd quarter worth approximately $254,000. Daiwa Securities Group Inc. boosted its holdings in shares of Icon by 19.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock worth $4,094,000 after purchasing an additional 4,546 shares during the last quarter. Frontier Capital Management Co. LLC boosted its holdings in shares of Icon by 97.6% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock worth $10,379,000 after purchasing an additional 35,253 shares during the last quarter. Peapack Gladstone Financial Corp acquired a new position in shares of Icon during the 2nd quarter worth approximately $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Icon by 58.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock worth $113,000 after purchasing an additional 289 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Company Profile

(Get Free Report)

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.